MX2020002880A - Proteínas que se unen a nkg2d, cd16 y a la molécula 1 similar a lectina de tipo c (cll-1). - Google Patents

Proteínas que se unen a nkg2d, cd16 y a la molécula 1 similar a lectina de tipo c (cll-1).

Info

Publication number
MX2020002880A
MX2020002880A MX2020002880A MX2020002880A MX2020002880A MX 2020002880 A MX2020002880 A MX 2020002880A MX 2020002880 A MX2020002880 A MX 2020002880A MX 2020002880 A MX2020002880 A MX 2020002880A MX 2020002880 A MX2020002880 A MX 2020002880A
Authority
MX
Mexico
Prior art keywords
antigen
antibody
binds
provides
nkg2d
Prior art date
Application number
MX2020002880A
Other languages
English (en)
Inventor
Bianka Prinz
Gregory P Chang
Ann F Cheung
William Haney
Bradley M Lunde
Original Assignee
Dragonfly Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc
Publication of MX2020002880A publication Critical patent/MX2020002880A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen proteínas de unión multiespecíficas que se unen a un antígeno CLL-1 asociado con tumor, el receptor NKG2D, y CD16, así como también composiciones farmacéuticas y métodos terapéuticos útiles para el tratamiento de cáncer.
MX2020002880A 2017-09-14 2018-09-13 Proteínas que se unen a nkg2d, cd16 y a la molécula 1 similar a lectina de tipo c (cll-1). MX2020002880A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762558510P 2017-09-14 2017-09-14
PCT/US2018/050916 WO2019055677A1 (en) 2017-09-14 2018-09-13 NKG2D, CD16, AND LIQUID-LIKE MOLECULE-1-LIKE PROTEINS (CLL-1)

Publications (1)

Publication Number Publication Date
MX2020002880A true MX2020002880A (es) 2020-10-01

Family

ID=65723086

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002880A MX2020002880A (es) 2017-09-14 2018-09-13 Proteínas que se unen a nkg2d, cd16 y a la molécula 1 similar a lectina de tipo c (cll-1).

Country Status (14)

Country Link
US (1) US20200277384A1 (es)
EP (1) EP3681532A4 (es)
JP (2) JP2020534269A (es)
KR (1) KR20200051789A (es)
CN (1) CN111432832A (es)
AU (1) AU2018331412A1 (es)
BR (1) BR112020005078A2 (es)
CA (1) CA3075857A1 (es)
EA (1) EA202090718A1 (es)
IL (1) IL273206A (es)
MA (1) MA50255A (es)
MX (1) MX2020002880A (es)
SG (1) SG11202002298PA (es)
WO (1) WO2019055677A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3579848T3 (da) 2017-02-08 2025-01-20 Dragonfly Therapeutics Inc Multispecifikke bindende proteiner til aktivering af naturlige dræberceller og terapeutiske anvendelser heraf til behandling af kræft
KR20240060739A (ko) 2017-02-20 2024-05-08 드래곤플라이 쎄라퓨틱스, 인크. Her2, nkg2d 및 cd16에 결합하는 단백질
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
SG11202007579TA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
SG11202007482WA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Antibody variable domains targeting the nkg2d receptor
JP7353576B2 (ja) 2018-02-20 2023-10-02 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法
EP3765516A2 (en) * 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
EP3833385A4 (en) 2018-08-08 2021-12-22 Dragonfly Therapeutics, Inc. PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
AU2019361096A1 (en) 2018-10-19 2021-06-03 Regents Of The University Of Minnesota NK engager molecules and methods of use thereof
GB2597851B (en) 2019-02-21 2024-05-29 Marengo Therapeutics Inc Antibody molecules that bind to NKP30 and uses thereof
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
CA3138972A1 (en) 2019-05-04 2020-11-12 Inhibrx, Inc. Clec12a-binding polypeptides and uses thereof
AR119393A1 (es) * 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
AU2020368163A1 (en) * 2019-10-15 2022-04-28 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and FLT3
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
CN115836088A (zh) * 2020-05-06 2023-03-21 蜻蜓疗法股份有限公司 结合nkg2d、cd16和clec12a的蛋白质
EP4146704A4 (en) * 2020-05-06 2024-08-28 Dragonfly Therapeutics, Inc. ANTIBODIES DIRECTED AGAINST CLEC12A AND USE THEREOF
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
IL307939A (en) 2021-04-26 2023-12-01 Millennium Pharm Inc Anti-CLEC12A antibodies and uses thereof
CN113817065B (zh) * 2021-09-06 2023-04-18 深圳市乐土生物医药有限公司 一种抗her2的多肽及其用途
CN115850476B (zh) * 2022-08-09 2023-09-05 合源康华医药科技(北京)有限公司 一种cll1抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040115198A1 (en) * 2001-02-28 2004-06-17 Fred Hutchinson Cancer Research Center Activation of lymphocyte populations expressing NKG2D using anti-NKG2D antibodies and ligand derivatives
WO2007002905A1 (en) * 2005-06-29 2007-01-04 University Of Miami Antibody-immune cell ligand fusion protein for cancer therapy
EP2014680A1 (en) * 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
DK2222706T4 (en) * 2007-12-14 2016-11-21 Novo Nordisk As Antibodies that bind to NKG2D and its use
WO2010080124A2 (en) * 2008-12-18 2010-07-15 Dana-Farber Cancer Institute, Inc. Nkg2d-fc for immunotherapy
US9163090B2 (en) * 2012-05-07 2015-10-20 Cellerant Therapeutics, Inc. Antibodies specific for CLL-1
PL2900694T3 (pl) * 2012-09-27 2018-12-31 Merus N.V. Dwuswoiste przeciwciała igg jako aktywatory komórek t
EP3405492B1 (en) * 2016-01-21 2020-10-21 Novartis AG Multispecific molecules targeting cll-1
KR20190123299A (ko) * 2017-02-27 2019-10-31 드래곤플라이 쎄라퓨틱스, 인크. Caix, ano1, 메소텔린, trop2, cea, 또는 클라우딘-18.2를 표적화하는 다중특이적 결합 단백질

Also Published As

Publication number Publication date
JP2020534269A (ja) 2020-11-26
WO2019055677A1 (en) 2019-03-21
US20200277384A1 (en) 2020-09-03
MA50255A (fr) 2021-05-26
AU2018331412A1 (en) 2020-03-26
CN111432832A (zh) 2020-07-17
IL273206A (en) 2020-04-30
EP3681532A1 (en) 2020-07-22
BR112020005078A2 (pt) 2020-10-13
CA3075857A1 (en) 2019-03-21
EA202090718A1 (ru) 2020-07-01
KR20200051789A (ko) 2020-05-13
EP3681532A4 (en) 2021-09-01
SG11202002298PA (en) 2020-04-29
JP2024099539A (ja) 2024-07-25

Similar Documents

Publication Publication Date Title
EA202090718A1 (ru) Белки, связывающие nkg2d, cd16 и лектиноподобную молекулу-1 c-типа (cll-1)
EA202091887A1 (ru) Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры
ZA202002338B (en) Novel bispecific polypeptide complexes
PE20231067A1 (es) Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos
JOP20200305A1 (ar) أجسام مضادة لـ entpd2، توليفة علاجات، وطرق استخدام الأجسام المضادة وتوليفة العلاجات
PH12020550408A1 (en) Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
PE20120549A1 (es) Proteinas biespecificas de union a antigenos
WO2018057735A8 (en) Antibodies for siglec-15 and methods of use thereof
MX2024013960A (es) Anticuerpos anti-ox40 y metodos de uso
TN2019000294A1 (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
MX2022007636A (es) Anticuerpos biespecificos caninizados y pares de union biespecificos para el tratamiento contra dermatitis atopica.
MX2021009852A (es) Anticuerpos humanos para pd-1.
JOP20180042A1 (ar) نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
EA202192090A1 (ru) Антигенсвязывающие белки против гамма-цепи рецептора il2
JOP20190236A1 (ar) أجسام مضادة لـ ilt4 وشظايا ارتباط بمولد ضد
MX2023010499A (es) Anticuerpos heterodimericos que se unen a cd3 y cldn6.
MX2021001711A (es) Proteínas biespecíficas modificadas.
MX2024001595A (es) Anticuerpos btla.
PE20221404A1 (es) Formulaciones farmaceuticas y regimenes de dosificacion para proteinas de union multiespecificas que se unen a her2, nkg2d y cd16 para el tratamiento del cancer
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
EA202190235A1 (ru) Антитела к cd33 и способы их применения
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
WO2020257789A3 (en) Anti-tim-3 antibodies
MX2022010161A (es) Proteínas biespecíficas anti-her2 diseñadas.
MX2022006147A (es) Metodos de tratamiento del cancer utilizando anticuerpos anti-ox40 en combinacion con anticuerpos anti-pd1 o anti-pdl1.